Kidney cancer drug attacks a major type of acute myeloid leukemia

A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with acute myeloid leukemia (AML), the most common and lethal form of adult leukemia, researchers at The University of Texas M. D. Anderson Cancer Center report in the Jan. 29 edition of the Journal of the National Cancer Institute.

If you want to include this story in your blog, copy and paste this formatted text: